Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity — Stella
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
(7 sites) United States
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey Memorial Sloan Kettering Monmouth, Middletown, New Jersey Memorial Sloan Kettering Bergen, Montvale, New Jersey Memorial Sloan Kettering Commack, Commack, New York Memorial Sloan Kettering Westchester, Harrison, New York Memorial Sloan Kettering Cancer Center, New York, New York Memorial Sloan Kettering Nassau, Uniondale, New York
Key details Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment target
~86 participants
Primary completion
July 2026
Last updated December 2025